Call +91 99159 33336

Name :
Email :
Company name :
Company address :
Contact No :
Product Interested In :
Time line for Purchase :

Pharma Updates

*DCGI to set up registry of legitimate online pharmacies to ensure compliance of norms and patient safety

*Update on the European Pharmacopoeia policy on elemental impurities

*Gujarat government announces Biotechnology Policy

*Continuous Bioprocessing: PAT Strategies in Support of Process Monitoring and Control to Enable Rapid Product Release

*Drug patents expiring in 2017? It's all smoke and mirrors - MedCity News

*Sun Pharma announces positive results in phase 3 study of eye care drug

*2017 RAPS' Regulatory Convergence


*Cholesterol is finally officially removed from Naughty List

*IPC adds 19 New Impurities Standards for related substance analysis

*FDA Issues List Of Priority Device Guidance For 2017

*ICH Q7 Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q&A

*When Does the Expiration of Pediatric Exclusivity Allow ANDA (or 505(b)(2) NDA) Approval?

*Cabinet okays sale of India's first pharma firm" >

*4 Common Record keeping Mistakes to Look Out For

*PCI instructs colleges to implement new rules & syllabus for B. Pharm & M. Pharm

*Govt invites domestic pharma firms to set up bulk drug clusters

*Watch Out for These 5 Hidden CAPA Pitfalls

*Are vaccine makers influencing India’s immunisation plan?

*Codeine to require a script from 2018

*Prices of 50 essential drugs slashed by up to 44%

*FDA Stresses Scientific Alignment, Not Harmonization For Global Biosimilars

*The Future of BioManufacturing

*FDA Warns Chinese Drugmaker for Refusing Inspection, Unsanitary Conditions

*No fresh approval for cocktail drugs

* Basics and Regulatory aspects Pharmacovigilance by PvPI IPC

*Current Good Manufacturing Practice Requirements for Combination Products

*GMP News: Revised USP Chapter on Analytical Instrument Qualification

*Change to IDA from CDSCO will usher in fresh wave of accountability & professionalism: Dr Jagashetty

*Japanese companies make cautious return to Indian pharma market